Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Clinical considerations in hypertensive black patients: the role of angiotensin II receptor blockers in combination with a diuretic
Autore:
Littlejohn, TW;
Indirizzi:
Piedmont Res Associates, Winston Salem, NC 27103 USA Piedmont Res Associates Winston Salem NC USA 27103 on Salem, NC 27103 USA
Titolo Testata:
BLOOD PRESSURE MONITORING
, volume: 6, anno: 2001, supplemento:, 1
pagine: S15 - S21
SICI:
1359-5237(200111)6:<S15:CCIHBP>2.0.ZU;2-I
Fonte:
ISI
Lingua:
ENG
Soggetto:
TO-MODERATE HYPERTENSION; LOW-DOSE HYDROCHLOROTHIAZIDE; ANTIHYPERTENSIVE THERAPY; DOUBLE-BLIND; LOSARTAN; ANTAGONISTS; TELMISARTAN; ENALAPRIL; EFFICACY; PLACEBO;
Keywords:
telmisartan; hydrochlorothiazide; hypertension; AT(1) receptor antagonist; combination therapy; hypertension in blacks;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
31
Recensione:
Indirizzi per estratti:
Indirizzo: Littlejohn, TW Piedmont Res Associates, 1901 S Hawthorne Rd,Suite 306, Winston Salem, NC 27103 USA Piedmont Res Associates 1901 S Hawthorne Rd,Suite 306 Winston Salem NC USA 27103
Citazione:
T.W. Littlejohn, "Clinical considerations in hypertensive black patients: the role of angiotensin II receptor blockers in combination with a diuretic", BL PRESS M, 6, 2001, pp. S15-S21

Abstract

Objective To evaluate the dose-response efficacy and tolerability of telmisartan, HCT, and their combination in black patients with mild-to-moderate hypertension (mean supine blood pressure 140/95-200/114 mmHg). Methods A 4-week, single-blind, placebo run-in period was followed by a 4 x 5 factorial, double-blind, 8-week treatment period. During the double-blind phase, 222 black patients (supine blood pressure 140/95-200/114 mmHg) were allocated randomly to groups to receive once-daily treatment with a combination of telmisartan (0, 20, 40, 80, or 160 mg) and HCT (0, 6.25, 12.5, or 25 mg). Blood pressure was measured at baseline and after 2, 4, and 8 weeks. Results Telmisartan 80 mg + HCT 12.5 mg reduced supine trough systolic blood pressure (SBP) by 21.5 mmHg and supine trough diastolic blood pressure (DBP; primary efficacy parameter) by 13.3 mmHg, which were 13.7/8.7 mmHg greater reductions than were produced by telmisartan 80 mg alone and 12.3/8.1 mmHg greater reductions than those produced by HCT 12.5 mg alone (P <0.01). Telmisartan 40 mg + HCT 12.5 mg reduced supine trough SBP/DBP by 14.3/10.0mmHg, 12.3/3.3 mmHg and 5.1/4.8 mmHg more than was achieved with the respective monotherapies. These effects attained statistical significance for tine comparisons with telmisartan 40 mg for SBP and HCT 12.5 mg for DBP (P less than or equal to0.05). A response surface analysis and therapeutic response rates confirmed the additive antihypertensive effects of telmisartan and HCT. All treatments were well tolerated, with side-effect profiles comparable to those of placebo. Conclusions Telmisartan 80 mg and HCT 12.5 mg combination therapy is effective and well tolerated in black patients with hypertension, improving antihypertensive activity beyond that achieved with the corresponding monotherapies. (C) 2001 Lippincott Williams & Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/01/20 alle ore 22:21:24